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1. Introduction
Disease was first time described as “Symmetrical central choroido-retinal disease occurring
in senile persons” in 1874 by Hutchinson. About 25 years ago, the term "age-related macul‐
opathy" was accepted and end stage of disease was acknowledged as age-related macular
degeneration [1]. AMD is leading cause of blindness worldwide in older patient population.
The highest risk of developing of AMD is in the population older than 65 years. With ageing
of population in many countries, more than 20 % might have the disease [2]. Advanced
forms of AMD are associated with visual progressive impairment. Visual acuity of this sub‐
jects decreases to practical blindness. This has big socioeconomic impact.
AMD is progressive chronic disease that is located in central retinal area (macula luthea –
yellow spot) [2]. Most visual lost is identified in late stages of AMD. There are 2 categories:
wet AMD and geographic atrophy. In wet AMD choroidal neovascularization breaks
through neuroretina. Leaking vessels, hemorrhages and lipid deposits lead to scarring proc‐
ess in macular area. All retinal structures including photoreceptors are destroyed. In geo‐
graphic atrophy occur progressive atrophy of retinal pigment epithelium and secondary
photoreceptors. To the end of 20th century was AMD practically untreatable. However, new
pharmaceuticals based on suppression of vascular endothelial growth factor (VEGF) have
completely changed the treatment of the disease [2]. Nearly 95 % of patients can be prevent‐
ed from visual lost, and nearly 40 % of them improve vision [2].
2. Epidemiology, risk factors, and natural history
Prevalence and incidence
In last 30 years were published many epidemiological studies on AMD. In a meta-analysis
of population-based studies in white people aged 40 years and older, the prevalence of early
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age-related macular degeneration was estimated to be 6.8% and late age-related macular de‐
generation 1.5%[3].
Results from the Baltimore Eye Study reported epidemiological data from other ethnic
groups. Late AMD was nine to ten times more prevalent in white participants than in black
ones [4]. Age-specific prevalence of late age-related macular degeneration in Asians is large‐
ly similar to that in white people [5].
In Asia population have often disease specific features. Many of them have polypoidal dila‐
tation of the choroidal vasculature. Polypoidal choroidal vasculopathy can account for 50%
of wet AMD cases in Asians, but only 8-13% in white people [5].
Another variant of AMD is retinal angiomatous proliferation (RAP), which accounts for
12-15% of neovascular age-related macular degeneration [6]. RAP usually not responds to
standard management of wet AMD.
There are few incidence studies on AMD. The US Beaver Dam Eye Study in the USA report‐
ed a 14.3% 15-year cumulative incidence for early AMD and 3.1% for late AMD in adults
aged 43-86 years [7].
3. Risk factors of AMD
The major risk factor for AMD is older age. More than 10% of people older than 80 years
have late AMD. Female sex has been inconsistently reported as a risk factor as well [3].
The major systemic risk factors include cigarette smoking [8]. Cigarette smoking in particu‐
lar is a strong and consistent risk factor for AMD. Smoking 20 cigarettes a day increases the
risk of double. Obesity is further systemic risk factor. This is connected with systemic riscs
of obesity. These patients are more likely to have hypertension and diabetes mellitus, which
are another risk factors [9,10]. People with AMD are also at increased risk of stroke [11].
Ocular risk factors for age-related macular degeneration include darker iris pigmentation,
previous cataract surgery, and hyperopic refraction. A meta-analysis suggested previous
cataract surgery was a strong risk factor for age-related macular degeneration, but this asso‐
ciation was not shown in a randomized clinical trial [12].
Table 1 summarizes the risk factors for age-related macular degeneration.
4. Genetic factors
Last ten years several genes have been associated to have role in pathogenesis of AMD [2].
AMD is disease that is tightly connected with inflammatory reaction. Inflammatory and im‐
munologic processes play major role in its pathogenesis. For this reason was identified com‐
plement factor H gene (CFH). Other confirmed genes in the complement pathway include
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C2, CFB, C3 and CFI.29-31. On the basis of large genome-wide association studies, HDL cho‐
lesterol pathway genes have been implicated, including LIPC and CETP, and possibly AB‐
CA1 and LPL.32-34 APOE in the LDL pathway might also be related to AMD [13]. The
collagen matrix pathway genes COL10A1 and COL8A1 and the extracellular matrix path‐
way gene TIMP3 have also been linked to age-related macular degeneration [14]. Finally,
genes in the angiogenesis pathway (VEGFA) have also been associated with age-related
macular degeneration in a meta-analysis of two AMD genome-wide association studies [14].
Older age, female sex
Cigarette smoking
Obesity, Hypertension, Diabetes mellitus
Low dietary intake of vitamins A, C, and E, and zinc
Low dietary intake of lutein and omega-3 fatty acids
Unhealthy lifestyle related to cardiovascular risk factors
Table 1. Risk factors for age-related macular degeneration (adapted from [2])
Genes modifying several biological pathways are in AMD. Complement and immune proc‐
esses, HDL cholesterol, and mechanisms involving collagen, extra-cellular matrix, and an‐
giogenesis pathways are associated with the onset, progression, and bilateral involvement of
AMD [2]. But it should be noted that genetic susceptibility can be modified by environmen‐
tal factors. Genetic variations can also influence differential responses to treatments for age-
related macular degeneration, an emerging research area [2].
Table 2 summarizes major genes associated with onset and progression of AMD
5. Clinical manifestations of the process of natural retinal aging
Aging is a physiological process involving all body organs and tissues. This process also af‐
fects the eye. It is a physiological process. That is not a manifestation of any disease. Each
body cell has a planned life cycle from its inception to apoptosis (cell death). Body tissue in
which there is no restoration of extinct mitotic cells (nerve tissue, retina), have a high inci‐
dence of manifestations of aging especially after the 75th year of life.
Clinical manifestation of retinal aging is mainly visible as a foveal reflex loss. Its background
is in the loss of cells from the inner retinal layers around the foveola and extending of foveal
avascular zone [15]. In macular zone are usually present small hard drusen, which are not
yet a manifestation of AMD [16]. In macula also occur tigers like irregularities in pigmenta‐
tion. Visual acuity remains on a physiological level unlike of subjects affected by AMD.
Doppler velocimetry demonstrates decrease of blood flow to the macular area [17]. Further
is detectable reduction of perifoveolar arterioles and venules together with enlargement of
foveal avascular zone [18] and reduction of retinal ganglion cells amount [19].
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Also can be diagnosed decrease of other visual functions in connection with the process of
aging. There are especially adaptation to darkness, contrast sensitivity, color vision and abil‐
ity of stereopsis [20].
CFH (complement factor H; chr 1)
ABCA4 (ATP-binding cassette transporter; chr 1)
COL8A1 (collagen type 8 alpha 1 subunit; chr 3)
CF1 (complement factor 1; chr 4)
VEGFA (vascular endothelial growth factor A; chr 6)
FRK/COL10A1 (fyn-related kinase/alpha chain of type X collagen; chr 6)
CFB (complement factor B [properdin]; chr 6)
C2 (complement component 2; chr 6)
ARMS2/HTRA1 (HtrA-serinepeptidase1; chr 10)
LIPC (hepatic lipase; chr 15)
CETP (cholesterylester transfer protein; chr 16)
APOE (apolipoprotein E; chr 19)
C3 (complement component 3; chr 19)
TIMP3 (tissue inhibitor of metalloproteinase 3; chr 22)
TNFRSF10A (tumor necrosis factor receptor superfamily 10a; chr 8)
Table 2. Summery of genes studied according to their impact on AMD (adapted from [2])
6. Classification and clinical features of age-related macular degeneration
Age-related macular degeneration can be divided into 2 categories: dry form (non-exuda‐
tive) and wet form (exudative). The dry form is very prevalent and affects about 85 to 90 %
of patients. The wet form occurs in the remaining 10 to 15 %. Impairment of central visual
acuity is much higher in wet form of AMD than in dry form. Wet form is responsible for 85
% of severe vision loss.
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6.1. Dry form of AMD
The dry form of AMD occurs independently on the choroidal neovascular membrane
(CNV). It is associated with chorioretinal atrophy with no obvious defects in Bruch’s mem‐
brane. Clinical studies show a decrease in chorioretinal blood flow [21]. Chorioretinal atro‐
phy leads to subsequent degeneration of the retinal pigment epithelium cells (RPE). It is
associated with involution of photoreceptors in the affected area [22]. The dry form of AMD
includes atrophy of the outer part of hematoretinal barrier (HRB) without appreciable leak‐
age. It seems that the barrier function is maintained and the area of atrophy remains dry.
Both forms of AMD are presented with painless loss of central vision. Individuals with dry
AMD will typically complain of blurred vision as well as difficulty seeing fine details clear‐
ly. In the advanced stages, atrophic macular areas often coalesce, creating central scotoma,
or blind spots, in the central visual field. This central visual loss compromises an individu‐
al's ability to perform basic tasks such as recognizing faces, reading signs, and other activi‐
ties of daily living. Individuals with wet AMD will commonly present with visual distortion
in which straight lines appear deformed. A hallmark of conversion from dry to wet AMD is
a sudden and profound loss or distortion of central vision. These visual changes occur as a
result of the acute degenerative changes occurring in the macula - most notably, subretinal
and intraretinal hemorrhages from choroidal neovascular membrane. Individuals will typi‐
cally have preserved peripheral vision in both processes [23].
6.2. Dry AMD
Dry AMD, the more common variety of the AMD, results from degeneration of outer retinal
cells (RPE cells) with subsequent profound retinal dysfunction (damage of photoreceptors
and retinal neurons).
The dry form of the disease is usually asymptomatic. Progression to the wet form may be
indicated by sudden, severe vision loss or new onset of visual distortion (metamorphopsia).
The dry form of the disease is characterized by macular drusen, however alterations in RPE
are visible. Intermediate to severe cases of the dry form are characterized by larger drusen
and geographic atrophy of RPE layer. This can cause severe vision loss [24].
Regular examinations are important to determine whether patients may benefit from certain
interventions. For patients over age 55 with no risk factors, a comprehensive eye exam every
one to two years is recommended. Patients with early-stage disease or a family history of the
condition may require closer follow-up. Those with an intermediate or advanced case of the
dry form of the disease should be advised to take a particular combination multivitamin rec‐
ommended in the Age-Related Eye Disease Study. These supplements reduce the risk of
progression to the wet form of the disease by 25%. However, patients with early-stage dis‐
ease may not benefit from such supplementation. Smoking cessation is associated with a
substantial reduction in the risk of progression to late-stage disease [24].
Self-monitoring with an Amsler grid (available online at www.macula.org/amsler-grid) is
critical and can help detect disease progression as early as possible. New onset of visual dis‐
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tortion noted on an Amsler grid, or any other sudden change in vision, may indicate pro‐
gression from dry to the wet form of AMD. In some cases, timely treatment can reduce the
risk of permanent loss of vision [24].
Patients who describe a sudden change in vision should be referred for urgent ophthalmic
evaluation [24].
Drusen
In early dry AMD, various lipid and protein-rich extracellular deposits accumulate under
the RPE [25]. Clinically, deposits of AMD are classified on fundoscopic features of morphol‐
ogy and size.
Drusen are a marker of age-related macular degeneration (AMD). Lesions similar to drusen,
both in histology and their clinical appearance, are also seen in choroidal tumours, chronic
inflammatory and degenerative conditions of the eye. Drusen are yellowish-white deposits
of extracellular material located between the retinal pigment epithelium (RPE) and the inner
collagenous zone of Bruch’s membrane. They are the result of ageing. Drusen seen in these
varied conditions have a similar clinical and histological appearance [26].
As  seen  through  the  ophthalmoscope,  drusen  are  dots  ranging  in  color  from  white  to
yellow,  sometimes  with  a  crystalline,  glittering  aspect.  The  origin  of  drusen  has  re‐
mained  unresolved  for  more  than  a  century.  Moreover,  there  is  no  agreement  as  to
whether  drusen in the absence of  other  ocular  abnormalities  always point  to  early age-
related macular degeneration [1].
Inside Bruch’s membrane we can differentiate several biochemical and anatomical changes
with aging, including collagenous thickening, calcification, and lipid infiltration, in the ab‐
sence of apparent retinal dysfunction. The accumulation of specific deposits under the RPE
is the hallmark histopathological feature of eyes with early AMD, when visual function is
still not irreversibly impaired. Histopathological examination defines three main types of
sub-RPE deposits on the basis of location, thickness, and content: basal laminar deposits
(BLamD), basal linear deposits (BLinD), and nodular drusen. BLamD is seen as amorphous
material of intermediate electron density between the plasma membrane and the basement
membrane of the RPE, often containing banded structures (wide-spaced collagen), patches
of electron-dense fibrillar or granular material, and occasionally, membranous debris [27].
They are distributed throughout the retina, including the periphery as well as the macula,
underlying not only cones but rods as well. BLinD are diffuse, amorphous accumulations
within the inner collagenous zone of BrM, external to RPE basement membrane, with simi‐
lar content variations [Green]. BLinD are characterized by coated and non-coated vesicles as
well as some membranous and empty profiles [28]. Biochemically, deposits contain phos‐
pholipids, triglycerides, cholesterol, cholesterol esters, unsaturated fatty acids, peroxidized
lipids, and apolipoproteins [29].
In contrast to BLamD and BLinD, nodular drusen are discrete, dome-shaped deposits within
the inner collagenous zone of BrM (i.e., external to the RPE basal lamina). Due to their loca‐
tion, nodular drusen are often contiguous with BLinD, and can be difficult to distinguish
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from BLinD without electron microscopy [25]. Differences between BLamD and BLinD are
seen on Figure 1.
A key factor influencing the classification of drusen is their size and shape. Simple aids, the
widest diameter of venous branches at the edge of the disc, which has a dimension of 125
microns, determine the size of drusen.
Drusen are classified according to their appearance and size in the two basic categories:
1. Hard drusen
Their size is smaller than 63 microns. Ophthalmoscopic examination shows us small and
well-demarcated yellow deposits (Figure 2.). This type of drusen is associated with very low
risk of progression to late forms of AMD. However the occurrence of more than 8 hard dru‐
sen is associated with an increased risk of occurrence soft drusen.
2. Soft drusen: their size is greater than 63 microns are not sharply defined; often coalesce
(Figure 3.). They are associated with higher risk of developing of wet AMD. If they af‐
fect foveal region they are often associated with the occurrence of metamorphopsia on
Amsler grid. Over time, soft drusen can confluent and form irregular detachment of the
RPE.
Figure 1. Schema of drusen in AMD. Legend: PhR – Photoreceptor, OSPhR – Outer Segment of Photoreceptor, RPE –
Retinal Pigment Epithelium, BLamD – Basal Laminar Deposits, BLinD – Basal Linear Deposits, BrM – Bruch’s Membrane,
CC – Choriocapillaris
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Figure 2. Hard drusen in macular region
Figure 3. Soft drusen in macular region
Occurrence of drusen, however, is not a static phenomenon. Their presence is characterized
by dynamic changes. Hard drusen can grow and change to soft drusen. Soft drusen can
grow and coalesce into large confluent bodies. This leads to detachment of the RPE. Another
change that can be seen is calcification. Inside drusen are visible cholesterol crystals. Drusen
with advancing age usually increased in their amount. Presence of soft drusen in both eyes
is an important risk factor in the development of advanced forms of AMD (geographic atro‐
phy of the RPE and CNV). Hard drusen are, however, frequently associated with the occur‐
rence of dry AMD [30].
Changes in retinal pigment epithelium
Irregularities in the RPE are associated with all stages of AMD. Focal hyperpigmentation
arises from changes at the level of the RPE. We can differentiate hyperpigmentation or RPE
cells, proliferation or migration of RPE cells into the subretinal space (Figure 4.). Focal hy‐
perpigmentation is commonly associated with chorioretinal anastomosis.
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Focal hypopigmentation is associated with areas of drusen, which leads to thinning of the
RPE cells layer and reduction of melanin content. Low melanin content is associated with a
high risk of transition to the wet form of AMD.
Geographic atrophy of RPE cells
Geographic atrophy (GA) of RPE is end-stage dry AMD. GA is characterized by well-cir‐
cumscribed area of RPE atrophy, which allows good visualization of the choroid and in end
stage of disease sclera (Figure 5., Figure 6.). The term geographic atrophy is not accurate
name for this stage, because it is not only RPE atrophy, but also choriocapilaris and retinal
atrophy. These three layers are inseparably joined together. The atrophy of one of them
leads to irreversible atrophy of the other twos. GA can occurs either as a primary form of
AMD, or followed by a secondary form after absorption of soft drusen, after flattening of
RPE detachment, or as a consequence of CNV regression, or rupture of the RPE. GA of RPE
is causing severe loss of visual acuity in 20% of AMD patients. The remaining 80% of the
severe losses of visual acuity in AMD is caused by CNV.
Figure 4. Hyperpigmentation and proliferation of RPE cells
Figure 5. Geographic atrophy of RPE (color image)
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Patients with primary GA are on average older than patients with wet AMD. Based on these
circumstances, it has been suggested that the GA process occurs as reaction to changes in
Bruch’s membrane in those eyes, which are not developed wet form of AMD.
Patients with GA RPE have problems with near vision in particular, even if it is retained
subfoveal RPE central area. These problems are caused by paracentral scotomas, abnormal
ability to adapt to the darkness that reduces visual acuity under dimmed lighting, and the
deterioration of contrast sensitivity [31]. Magnifying aids paradoxically don’t bring a large
profit because it carries the magnified image into the paracentral absolute scotomas. The pa‐
tient's vision during the day varies depending on the ability to find a central area function‐
ing retina within the zone of GA [32].
Figure 6. Geographic atrophy of RPE (red free image)
Long-term prognosis of visual acuity in GA is individual. It depends mainly on the loca‐
tion of the first location of GA. Interval from the developing of first spot to the GA with
legal  blindness  is  about  9  years  [33].  The  average  rate  of  progress  of  GA is  about  139
microns per year. Affected eyes have 8 % annual risk of a decline of visual acuity value
from 20/50 to 20/100 [34].
GA RPE occurs bilaterally. The second eye is affected by in about 50%. Area of GA in the
second eye is around 20 % smaller. With the development of GA in one eye decreases the
risk of CNV in both eyes (i.e. wet AMD) [31].
Research that is based on the RPE injury hypothesis postulate that the pathogenesis and pro‐
gression of dry macular degeneration is characterized by three distinct stages:
1. Initial RPE oxidant injury causes extrusion of cell membrane debris together with de‐
creased activity of matrix metalloproteinases (MMPs), under the RPE as BLamD.
2. RPE cells are subsequently stimulated to increase synthesis of MMPs and other mole‐
cules responsible for extracellular matrix removal affecting both RPE basement mem‐
brane and BrM [35]. This process leads to progression of BLamD into BLinD and drusen
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by admixture of blebs into BrM, followed by the formation of new basement membrane
under the RPE to trap these deposits within BrM [36].
3. Macrophages are recruited to sites of RPE injury and deposit formation. Macrophage
recruitment may be beneficial or harmful depending upon their activation status at the
time of recruitment [37]. Nonactivated or scavenging macrophages may remove depos‐
its without further injury. Activated or reparative macrophages, through the release of
inflammatory mediators, growth factors, or other substances, may promote complica‐
tions and progression to the late forms of the disease [37].
6.3. Wet form of AMD
Wet AMD occurs less commonly but is far more aggressive when compared with dry AMD.
Wet AMD results from the development of neovascularization, or new blood vessel growth,
beneath the retina. These abnormal blood vessels may break into the retinal cell layers. The
leakage of fluid and proteins from these vessels causes scar formation throughout the macu‐
la, which ultimately results in deterioration of central vision. Wet AMD tends to be far more
severe than dry AMD.
The wet form of AMD is characterized by occurrence of RPE detachment, choroidal neovas‐
cular membrane (CNV), subretinal hemorrhage in the macula. The terminal stage of wet
AMD is disciform scar (Figure 7.).
In the last decade, the wet form of AMD allocated an additional 2 clinical units: angiomatose
retinal proliferation (RAP) and polypoidal choroidal vasculopathy (PCV) (see below).
Figure 7. Disciform scar
Retinal pigment epithelium detachment
Their prognosis isn’t good if central part of fovea is affected. [38]. RPE detachment is gener‐
ally characterized by elevation of RPE layer from the Bruch’s membrane. RPE detachment is
divided into 4 categories.
1. Drusen RPE detachment (Figure 8.)
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Drusen RPE detachment is formed in the later stages of multiple connecting soft drusen,
which elevate the RPE layer from Bruch’s membrane. Drusen RPE detachment is a high risk
due to the development of CNV [38]. On the fluorescein angiography (FA) we can see in ear‐
ly phase hyperfluorescence of soft drusen, which isn’t widening until the late stages.
Figure 8. Drusen RPE detachment
2. Serous RPE detachment (Figure 9., Figure 10.)
Serous RPE detachment is roughly bounded elevation of the RPE cells, containing serous
fluid that is usually clear, but may be turbid. On the FA we see early hyperfluorescence,
which is sharply bounded, but not noticeable leakage.
3. Hemorrhagic RPE detachment (Figure 11.)
4. Fibrovascular RPE detachment (Figure 12.)
Hemorrhagic and vascularized RPE detachments are very close, because both contain the
CNV. They differ from each other in principle, only the extent of bleeding, which in hemor‐
rhagic RPE detachment greater. Angiographic picture of hemorrhagic RPE detachment is
different from the vascularized because hemoglobin overlaps fluorescence, and the extent of
CNV is not completely well defined. In unclear cases are possible to use indocyanine green
angiography (ICGA), which can display the vascular structure of the retina and choroid de‐
spite hemoglobin.
The clinical course of RPE detachment may be as follows:
1. Persistent RPE detachment
Persistent RPE detachment can be stabilized without the presence of CNV. Over time, may
be slowly progressing in its size [38].
2. Flattened RPE detachment
Flattening of the RPE detachment is uncommon and when it occurs, usually develops in the
affected area geographic atrophy of the RPE [39].
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Figure 9. Serous RPE detachment
Figure 10. Serous RPE detachment on fluorescein angiography
Figure 11. Hemorrhagic RPE detachment
Classification and Clinical Features of AMD
http://dx.doi.org/10.5772/53762
117
3. Rupture of RPE
RPE rupture is very unfavorable state accompanying the process of development of RPE
detachment  [40].  It  occurs  mostly  at  the  edge  of  detachment  at  the  transition  attached
and detached RPE. The RPE constricts away from location of rupture to the center of the
detachment.  If  it  is  affected subfoveal  area,  there  is  detected a  rapid decrease  in  visual
acuity.  In this case,  the photoreceptors had lost  contact  with the RPE cells,  and there is
an absolute central scotoma. In the course of rupture usually occurs subretinal bleeding.
Less  frequently  develops  CNV,  which  is  very  aggressive  and rapidly  progresses  to  the
disciform scar [40].
4. Development of CNV
But the most common complication of RPE detachment is the appearance of CNV. Increas‐
ing age is the basic risk factor of development of CNV in subjects with RPE detachment.
CNV formation is rare in patients under 56 years of age, occurs in 29 % of those aged 56-75
years and affects 62.5 % of subjects in the group over 75 years. Another study showed that
elderly patients have a larger RPE detachment with more fluid than younger and more often
develop CNV [41].
Choroidal neovascular membrane
CNV occurs when occurs the rupture of Bruch’s membrane. Newly formed blood vessels
from choroid grow first into the space under the RPE and later under the subretinal space.
Size of edema of neuroretina is a sign of CNV activity. Attempt to unify the classification of
CNV has become a necessity. Based on this was defined by the term classic and occult CNV.
A typical picture of CNV includes subretinaly localized grayish lesion, which can vary in
size, location and thickness. If the membrane has a classic character, the lesion is usually
well defined and its edges are lined with subretinal hemorrhages (Figure 13.).
On the FA it can be seen from early stages well-demarcated lesion that not increase in it size
to the late stages of FA (Figure 14., Figure 15.).
Figure 12. Fibrovascular RPE detachment
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Figure 13. Classic CNV
Figure 14. Early stage of classic CNV on FA, well-demarcated lesion with block of fluorescence on its border due to
subretinal hemorrhage
Figure 15. Late stage of classic CNV on FA, well-demarcated lesion that not increase in its size from early stage
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The size of occult membranes is most evident at biomicroscopy. Changes are visible at the
level of the RPE (movement of RPE cells, RPE detachment). There may occur subretinal
hemorrhages. Oedema of neuroretina is noticeable (Figure 16.).
Figure 16. Occult CNV
Figure 17. Early stage of occult CNV on FA, lesion is not clearly visible, leakage is very low and not well demarcated
Location of CNV in respect to the position of RPE
This classification is put into clinical practice for the first time in late 1960 by Gass [42].
Based on the findings on fluorescence angiography (FA) distinguishes two basic types of
CNV: classic and occult.
Occult CNV (according to Gass classification type I) is characterized by the development of
the neovascular complex and RPE choriocapillaris. CNV complex is characteristic for the be‐
ginning stages of wet AMD (Figures 16-18.).
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Figure 18. Late stage of occult CNV on FA, CNV size increases when compare to the early stage
Classic CNV (according to Gass classification type II) causes the spread of CNV complex in
the space between the RPE and neuroretina. We can say that the classic CNV arises from oc‐
cult CNV to a breach of continuity Bruch’s membrane (Figures 13-15.).
Classification of CNV according to the center of the fovea
Entire CNV complex localization in respect to the center of the fovea plays a crucial role in
deciding on the method of subsequent therapy. Localization is possible only by using of
high-quality FA.
Depending on the position of CNV according to the fovea center we can diagnose 3 forms of
CNV. The most common form is subfoveal localization, which has a CNV complex located
beneath the center of the fovea. Another form is juxtafoveal localization. In this case, the
CNV complex is located at a distance of 1 to 199 microns from the center of the fovea. The
least frequent localization is extrafoveal location. Distance from the center of CNV complex
fovea is larger than 200 microns.
Special clinical units within the wet form of AMD
In the last decades passed classification of wet AMD further development. There were creat‐
ed 2 new clinical entities distinguished from the model of classic and occult CNV: retinal an‐
giomatous proliferation (RAP) and polypoidal choroidal vasculopathy (PCV).
Retinal Angiomatous Proliferation (RAP)
Yannuzzi created this term in order to describe the basic characteristics of clinical entity, in
which the formation of neovascularization begins within retina [43].
RAP represents about 10 – 15 % of newly diagnosed cases of wet AMD [44]. It occurs more
frequently in elderly patients [43]. Most commonly occurs in Caucasians, in contrast to PCV,
which is more common in pigmented races [45].
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The disease is divided into 3 clinical stages
Stage I – intraretinal neovascularization: New RAP lesions develop typically outside the fo‐
veal avascular zone, i.e. extrafoveal. The course is initially asymptomatic. Intraretinal neo‐
vascularization (IRN) begins in the deep capillary plexus outside the center of the fovea.
During development, the most typically spread in the vertical direction, i.e. between the ex‐
ternal and the internal limiting membrane. IRN that is spreading sideways is not typical in
initial stages. Biomicroscopically can be observed capillary dilation with a large network of
nourishing blood vessels and intraretinal haemorrhages. Haemorrhages are usually very
discreet compared to subretinal hemorrhages accompanying classic and occult CNV and es‐
pecially PCV [45].
Stage II - subretinal neovascularization: This stage is diagnosed if the complex of IRN moves
between photoreceptors and RPE. This area develops detachment of neuroretina with corre‐
sponing edema. Intraretinal haemorrhages are more noticeable than in stage I. If the lesion
extends into the subretinal space, there can be diagnosed small subretinal haemorrhage. At
this stage, there is often retino-retinal anastomosis, which has afferent arteriole and efferent
venule. Serous RPE detachment can be diagnosed if is IRN connected with subretinal CNV.
Stage III - CNV: In stage III is diagnosed already typical CNV combined with vascularized
RPE detachment. During the development of CNV is then in subretinal space formed cho‐
rioretinal anastomosis like clear communication between the retinal bloodstream and the
choriocapilaris. CNV is predominantly perfused by the vascular system of the choroid. In
the end stage is then evident disciform scar.
Pathophysiological mechanism of RAP development is not explained in detail till now. It is
assumed the proportion of VEGF produced by RPE cells [46]. Thus neovascularization be‐
gins intraretinally and later subretinally. Secondarily creates RPE detachment with the oc‐
cult CNV [47]. Reduction of Bruch membrane permeability for VEGF may signify increases
its intraretinal concentration. This situation is main cause of intraretinal neovascularization
[48]. Another theory shows that the oxidative stress leads to migration of RPE cells, both
subretinally and intraretinally. This leads to the production of VEGF and stimulation of neo‐
vascularization in an atypical location [49].
Diagnostic
Basic diagnostic modality is beside biomicroscopy FA examination. In stage I leakage occurs
at the region intraretinal neovascularization. In this area is also biomicroscopicaly demon‐
strated edema with accumulation of vascular loops and leakage of dye on FA. RAP can at
this stage be erroneously mistaken for another microangiopathy, such as incipient diabetic
maculopathy. RAP stage II and I may be misdiagnosed as classic CNV. In stage III we can
see on FA finding very close to vascularized RPE detachment. It is therefore often diagnosed
as occult CNV [43].
ICGA usually brings enough light to the uncertain cases. In stage I is observed focal hyper‐
fluorescence in retinal circulation, which has the character of IRN [44]. There can often be
diagnosed retino-retinal anastomosis. In stage II IRN is visible inside and under the retina.
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Figure 19. Stage III of RAP. Temporally in macula is chorioretinal anastomosis.
Figure 20. Stage III of RAP on FA, early phase
Figure 21. Stage III of RAP on FA, late phase, leakage dye from CNV is visible
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For location of IRN have to be used pseudo stereo view to state the position of neovasculari‐
zation in the vertical axis. Hot spot for RAP must be distinguished from another hot spots,
e.g. inside the choroid. In stage III is visible, a connection of choroidal and retinal neovascu‐
larization (Figure 19.-21.). This creates a complex neovascularization, which has the charac‐
ter of vascularized RPE detachment. In some cases, we trace chorioretinal anastomosis.
Polypoidal Choroidal Vasculopathy (PCV)
This clinical entity has been in detail described and classified by Yannuzzi in 1990 as a pecu‐
liar hemorrhagic disorder of the macula, characterized by recurrent sub-retinal and sub-reti‐
nal pigment epithelium bleeding in middle aged black women [50]. Pathogenesis of the
disease is not completely understood. The primary pathological changes that occur are sac-
like extension of choroidal vessels, which are sacculated polypoidal nature. Clinically it is
manifested by multiple hemorrhagic PCV and serose RPE detachment accompanied by reti‐
nal edema [50]. PCV is a special type of CNV in wet AMD [45].
PCV usually occurs in pigmented races between 50 - 65 years of age. Originally it was
thought that the disease affected only black women. According to published data, the dis‐
ease occurs in men, the ratio of affected women compared to men is 4,7:1 [51]. Prevalence
varies between 4-10% in subjects with newly diagnosed wet AMD.
For the basic clinical picture of PCV is characterized by the absence drusen accompanied by
haemorrhagic or serous RPE detachment. Other symptoms are: minimal signs of scarring,
vitreous hemorrhage, and signs of intraocular inflammation. The disease usually occurs bi‐
laterally [50], although it is described one-side occurrence [52]. The main factor contributing
to the development of PCV seems to be the long-term chronic hypoxia by RPE detachment
together with destructive effect of hard exudates.
Vascular structure PCV is located in choroid. Distinguish by size we have small, medium
and large PCVs. PCV lesions reach a larger size if there are affected larger choroid vessels.
When are affected medium choroid vessels, the lesions are smaller. Their diagnosis is more
difficult because they don’t have a characteristic image like a larger lesions [50].
PCV is located mostly around the optic disc. Some works but also show localization in the
central periphery or in the central macular area [53]. PVC may be present as a single lesion,
or may be multiple. Topographically are lesions localized to the area under the Bruch’s
membrane. The results of these studies are documented on OCT [54].
Natural course of the disease
PCV has the character of a chronic disease that manifests by serosanguinolent RPE detach‐
ment often near the optic nerve. Disease comes in multiple relapses, and patients have main‐
tained good visual acuity for long time. Chronic RPE detachment usually results to the
creation scaring plaque beneath the RPE, which is hardly distinguishable from classical dis‐
ciform scar that develops as a terminal stage of the wet form of AMD. Polyps can have very
specific progress. They occlude often spontaneously, and after some time are again perfund‐
ed. If are polyps located in the central subfoveal area in the terminal stage of the disease can
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occur RPE atrophy and chronic cystoid retinal changes. Rarely may arise massive subretinal
and intravitreal hemorrhage, which is usually fatal and final visual acuity is poor [55].
Diagnostic
Blood vessels occurring with PCV have a characteristic shape. Form a bag-like aneurysms,
RPE over them has a characteristic red-orange color (Figure 22., Figure 23.).
In contrast, blood vessels in other types of CNV are made from very small vascular knitting
and are usually gray-green color. The thickness of the choroid is smaller in other types of
CNVs. In PCV is choroid thicker.
Figure 22. PCV in maculopapilar bundle, color image
Figure 23. PCV in maculopapilar bundle, red free image
FA may in some cases provide a diagnosis of PCV (Figure 24., Figure 25.).
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Figure 24. PCV in middle phase of FA, leakage from polyps is visible, in temporal part of macula is detected RPE de‐
tachment
However, the basic diagnostic modality is in the diagnosis of PVC ICGA. Only on ICGA can
be diagnosed bag-like extension of choroidal vessels [56]. In the early phase of ICGA fill up
large PCV vessel before filling of retinal vessels. Neighborhood of PCV lesions remains hy‐
pofluorescent. Late stage of ICGA shows choroidal polyps. They are closely associated with
large chorioidal vessels (Figure 26., Figure 27.).
In the initial phase of the angiogram polyps are usually smaller than in the late phase. This
corresponds to the red-orange lesions, which are detectable by biomicroscopy. In the late
stage, there is a reverse phenomenon. Center of the lesion becomes hypofluorescent and
around the polyp occurs hyperfluorescence. At a very late stage angiogram can occur wash‐
out of dye. This phenomenon is only seen in the lesions without leaking; leaking lesions re‐
main hyperfluorescent [56].
Figure 25. PCV in late phase of FA, leakage from polyps is visible, 2 RPE detachments are located on temporal upper
vascular arcade and in temporal part of macula
Age-Related Macular Degeneration - Etiology, Diagnosis and Management - A Glance at the Future126
Figure 26. PVC, early stage on ICGA
Figure 27. PCV, late stage on ICGA, polyps are visible near the optic disc
OCT examination demonstrates elevation of RPE layer, which corresponds to the red-orange
lesions detected during biomicroscopic examination. PCV is manifested against serous RPE
ablation by greater prominence of RPE layer [54].
Differential diagnosis
Differential diagnosis distinguishes PCV from other vascular abnormalities, inflammatory
conditions of the retina and choroid, other types of CNV and choroidal tumors. Improved
diagnostic methods and clarifying the pathophysiological mechanisms lead to the correct di‐
agnosis of PCV more often than before.
In diagnostic help both FA and ICGA. CNV in PCV leaks already at an early phase, so as
CNV different origin. In the late stage, the lesion on the basis of PVC may have washed out
the dye [56]. If a bag-like aneurysms leak, in their neighborhood is evident late dye leakage
(Figure 26., Figure 27.).
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CNV on the basis of PVC, rarely undergo to fibrose unlike other types of CNV in AMD. RPE
detachment associated with PCV almost doesn’t fibrose, whereas RPE detachment associat‐
ed with occult CNV fibrose very often and has a very poor prognosis [50].
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